Next-generation therapies for pancreatic cancer.

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-01-01 Epub Date: 2024-02-28 DOI:10.1080/17474124.2024.2322648

Conor W Buckley, Eileen M O'Reilly

{"title":"Next-generation therapies for pancreatic cancer.","authors":"Conor W Buckley, Eileen M O'Reilly","doi":"10.1080/17474124.2024.2322648","DOIUrl":null,"url":null,"abstract":"Introduction: Pancreas ductal adenocarcinoma (PDAC) is a frequently lethal malignancy that poses unique therapeutic challenges. The current mainstay of therapy for metastatic PDAC (mPDAC) is cytotoxic chemotherapy. NALIRIFOX (liposomal irinotecan, fluorouracil, leucovorin, oxaliplatin) is an emerging standard of care in the metastatic setting. An evolving understanding of PDAC pathogenesis is driving a shift toward targeted therapy. Olaparib, a poly-ADP-ribose polymerase (PARP) inhibitor, has regulatory approval for maintenance therapy in BRCA-mutated mPDAC along with other targeted agents receiving disease-agnostic approvals including for PDAC with rare fusions and mismatch repair deficiency. Ongoing research continues to identify and evaluate an expanding array of targeted therapies for PDAC.Areas covered: This review provides a brief overview of standard therapies for PDAC and an emphasis on current and emerging targeted therapies.Expert opinion: There is notable potential for targeted therapies for KRAS-mutated PDAC with opportunity for meaningful benefit for a sizable portion of patients with this disease. Further, emerging approaches are focused on novel immune, tumor microenvironment, and synthetic lethality strategies.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"55-72"},"PeriodicalIF":3.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10960610/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2024.2322648","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Pancreas ductal adenocarcinoma (PDAC) is a frequently lethal malignancy that poses unique therapeutic challenges. The current mainstay of therapy for metastatic PDAC (mPDAC) is cytotoxic chemotherapy. NALIRIFOX (liposomal irinotecan, fluorouracil, leucovorin, oxaliplatin) is an emerging standard of care in the metastatic setting. An evolving understanding of PDAC pathogenesis is driving a shift toward targeted therapy. Olaparib, a poly-ADP-ribose polymerase (PARP) inhibitor, has regulatory approval for maintenance therapy in BRCA-mutated mPDAC along with other targeted agents receiving disease-agnostic approvals including for PDAC with rare fusions and mismatch repair deficiency. Ongoing research continues to identify and evaluate an expanding array of targeted therapies for PDAC.

Areas covered: This review provides a brief overview of standard therapies for PDAC and an emphasis on current and emerging targeted therapies.

Expert opinion: There is notable potential for targeted therapies for KRAS-mutated PDAC with opportunity for meaningful benefit for a sizable portion of patients with this disease. Further, emerging approaches are focused on novel immune, tumor microenvironment, and synthetic lethality strategies.

查看原文本刊更多论文

胰腺癌的新一代疗法。

简介：胰腺导管腺癌（PDAC）是一种常见的致死性恶性肿瘤，给治疗带来了独特的挑战。目前治疗转移性胰腺导管腺癌（mPDAC）的主要方法是细胞毒性化疗。NALIRIFOX（脂质体伊立替康、氟尿嘧啶、白杉兰、奥沙利铂）是治疗转移性癌症的新兴标准疗法。对 PDAC 发病机理的不断深入了解推动了向靶向治疗的转变。多ADP核糖聚合酶（PARP）抑制剂奥拉帕利（Olaparib）已获得监管部门批准，用于BRCA突变mPDAC的维持治疗，其他靶向药物也获得了疾病诊断批准，包括用于罕见融合和错配修复缺陷的PDAC。目前的研究仍在继续，以确定和评估越来越多的 PDAC 靶向疗法：本综述简要概述了PDAC的标准疗法，并重点介绍了当前和新兴的靶向疗法：专家观点：KRAS突变型PDAC的靶向疗法具有显著的潜力，有机会使相当一部分该病患者从中获益。此外，新出现的方法侧重于新型免疫、肿瘤微环境和合成致死策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.